Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC (SRPT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/09/2018 11/12/2018 11/13/2018 11/14/2018 11/15/2018 Date
125.46(c) 120.82(c) 116.77(c) 111.99(c) 118.96(c) Last
3 118 158 1 151 842 1 492 624 2 079 296 1 243 748 Volume
-5.67% -3.70% -3.35% -4.09% +6.22% Change
More quotes
Financials (USD)
Sales 2018 301 M
EBIT 2018 -261 M
Net income 2018 -275 M
Finance 2018 285 M
Yield 2018 -
Sales 2019 420 M
EBIT 2019 -193 M
Net income 2019 -194 M
Finance 2019 298 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 23,9x
EV / Sales2019 17,1x
Capitalization 7 484 M
More Financials
Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases.It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug... 
More about the company
Surperformance© ratings of Sarepta Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SAREPTA THERAPEUTICS INC
11/10SAREPTA THERAPEUTICS : Announces Pricing of $500,000,000 Public Offering of Comm..
AQ
11/09SAREPTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other E..
AQ
11/09Sarepta collects half a billion in follow-on
AQ
11/09Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Com..
GL
11/07Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Commo..
GL
11/05SAREPTA THERAPEUTICS : to Present at Credit Suisse 27th Annual Healthcare Confer..
AQ
11/02SAREPTA THERAPEUTICS : to Present at Credit Suisse 27th Annual Healthcare Confer..
AQ
11/01SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
11/01SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
10/31SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
More news
Sector news : Bio Therapeutic Drugs
11/12Ziopharm in Supply Agreement with Regeneron to Study Glioblastoma Treatment
DJ
11/06Regeneron, Sanofi Get FDA Priority Review for Dupixent in Adolescents
DJ
11/06REGENERON PHARMACEUTICALS : Posts Higher Profits Led By Treatment Advances
DJ
11/06REGENERON PHARMACEUTICALS : Sanofi and Regeneron's Dupixent gets more positive f..
RE
11/01LONZA : sells water care business for $630 million
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
11/15$SRPT bullish engulfing, awesome bounce 
11/14$SRPT tag 200DMA today 
11/13$SRPT gap fill and 200SMA coming up together imminently, will be a great plac.. 
11/13$SLDB Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE Cli..
2
11/13$85.21 Million in Sales Expected for Sarepta Therapeutics Inc $SRPT This Quar.. 
More tweets
Qtime:99
News from SeekingAlpha
11/15SOLID BIOSCIENCES : A Classic Story Of Opportunistic Investing 
11/13BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Voyager's Update, Sarepta's Raise, Nektar.. 
11/13Solid Bio up 18% on advancement of DMD gene therapy SGT-001 
11/11BLUEPRINT MEDICINES : An Infrequent, Timely Buy 
11/09Sarepta prices $500M stock offering at $131 
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 195 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC101.28%7 484
GILEAD SCIENCES-1.01%91 265
VERTEX PHARMACEUTICALS13.65%42 060
REGENERON PHARMACEUTICALS-9.01%35 862
GENMAB-10.20%8 631
NEUROCRINE BIOSCIENCES, INC.28.24%7 810